logo image
search icon
RNA Therapy Clinical Trials Market

RNA Therapy Clinical Trials Market Size, Share & Trends Analysis Report by By Modality (RNA interference, Antisense therapy, Messenger RNA, and Oligonucleotide, non-antisense, non-RNAi), By Phase, By Therapeutic Areas (Rare Diseases, Anti-infective, Anticancer, Neurological), Region And Segment Forecasts, 2023-2031

Report ID : 1964 | Published : 2024-10-28 | Pages: 180 | Format: PDF/EXCEL

The Global RNA Therapy Clinical Trials Market Size is valued at 2.45 billion in 2022 and is predicted to reach 3.32 billion by the year 2031 at a 3.6% CAGR during the forecast period for 2023-2031.

RNA Therapy Clinical Trials Market

The process of testing and evaluating the safety and effectiveness of therapeutic interventions based on RNA molecules is referred to as RNA therapy clinical trials. RNA therapy is a large group of treatments that use various forms of RNA molecules to target and modulate gene expression, such as messenger RNA (mRNA), small interfering RNA (siRNA), and antisense oligonucleotides. Various factors influence the market dynamics for RNA treatment clinical trials. As interest in and investment in RNA therapy has grown, so has competition among businesses developing RNA-based medications. Established pharmaceutical businesses, as well as startups and biotech companies, entered the industry, spurring innovation and clinical trial activity.

However, due to the pandemic, many active RNA treatment clinical trials were either halted or delayed. Clinical study activities were halted due to lockdowns, travel restrictions, and worries about the safety of trial participants and staff. 

Competitive Landscape:

Some of the RNA Therapy Clinical Trials Market players are: 

  • IQVIA
  • ICON Plc
  • Laboratory Corporation of America Holdings
  • Charles River Laboratories International, Inc.
  • PAREXEL International Corp.
  • Syneos Health
  • Medpace Holdings, Inc.
  • PPD Inc.
  • Novotech
  • Veristat, LLC 

Market Segmentation:

The RNA Therapy Clinical Trials Market is segmented on the basis of modality, clinical trials, and therapeutic areas. Modality segment includes RNA interference, Antisense therapy, Messenger RNA, and Oligonucleotide, non-antisense, non-RNAi. The clinical trials segment includes Phase I, Phase II, Phase III, and Phase IV. By therapeutic areas, the market is segmented into Rare Diseases, Anti-infective, anticancer, Neurological, Alimentary/Metabolic, Musculoskeletal, Cardiovascular, Respiratory, Sensory, and Others.

Based On The Product, The Messenger RNA Segment Is Accounted As A Major Contributor In The RNA Therapy Clinical Trials Market

The Messenger RNA category is expected to hold a major share of the global RNA Therapy Clinical Trials Market in 2022. The COVID-19 pandemic pushed the development and deployment of mRNA-based vaccines, particularly Pfizer-BioNTech and Moderna's COVID-19 vaccines. Because of the effectiveness of these mRNA vaccines, mRNA technology has received attention and demonstrated potential in the fight against infectious diseases. Furthermore, mRNA therapies have various potential applications in a variety of disease conditions. They can be used to encode specific proteins that produce therapeutic antibodies, trigger an immune response, or restore protein function.

Phase II Segment Witnessed Growth At A Rapid Rate

The Phase II segment is projected to grow at a rapid rate in the global RNA Therapy Clinical Trials Market. Increasing R&D investment and increasing non-industry-sponsored and industry-sponsored phase II clinical studies are important contributors to the segment's growth. Phase 2 studies enable the optimal dose and dosing schedule for RNA treatments to be determined.

In The Region, The North American RNA Therapy Clinical Trials Market Holds A Significant Revenue Share

The North American RNA Therapy Clinical Trials Market is expected to report the highest market share in terms of revenue in the near future. This is due to the early acceptance of RNA therapeutics, a strong research infrastructure, a favorable regulatory environment, and a large biotechnology and pharmaceutical industry. Furthermore, numerous RNA therapies have previously acquired FDA approval, and many are currently through various phases of clinical research to demonstrate their efficacy for a variety of illnesses.

Over the projection period, Asia Pacific is expected to increase significantly. Academic institutions, research organizations, and biotech firms are actively involved in RNA-based research in countries such as China, Japan, South Korea, and Singapore, resulting in an expanding pipeline of potential RNA therapeutics and an increase in the number of clinical studies in the field.

RNA Therapy Clinical Trials Market Report Scope:

Report Attribute

Specifications

Market Size Value In 2022

USD 2.45 Bn

Revenue Forecast In 2031

USD 3.32 Bn

Growth Rate CAGR

CAGR of 3.6 % from 2023 to 2031

Quantitative Units

Representation of revenue in US$ Bn and CAGR from 2023 to 2031

Historic Year

2019 to 2022

Forecast Year

2023-2031

Report Coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments Covered

By Modality, Clinical Trials, And Therapeutic Areas

Regional Scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country Scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; South East Asia

Competitive Landscape

IQVIA; ICON Plc; Laboratory Corporation of America Holdings; Charles River Laboratories International, Inc.; PAREXEL International Corp.; Syneos Health; Medpace Holdings, Inc.; PPD Inc.; Novotech; Veristat, LLC.

Customization Scope

Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape.

Pricing And Available Payment Methods

Explore pricing alternatives that are customized to your particular study requirements.

Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global RNA Therapy Clinical Trials Market Snapshot

Chapter 4. Global RNA Therapy Clinical Trials Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. COVID-19 Impact Analysis

Chapter 5. Market Segmentation 1: By Modality Estimates & Trend Analysis
5.1. By Modality & Market Share, 2019-2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2031 for the following By Modality:

5.2.1. RNA interference
5.2.2. Antisense therapy
5.2.3. Messenger RNA
5.2.4. Oligonucleotide, non-antisense, non-RNAi

Chapter 6. Market Segmentation 2: By Clinical Trials Phase Estimates & Trend Analysis

6.1. By Modality & Market Share, 2019-2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2031 for the following By Clinical Trials Phase:

6.2.1. Phase I
6.2.2. Phase II
6.2.3. Phase III
6.2.4. Phase IV

Chapter 7. Market Segmentation 3: By Therapeutic Areas Estimates & Trend Analysis
7.1. By Modality & Market Share, 2019-2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2031 for the following By Therapeutic Areas:

7.2.1. Rare Diseases
7.2.2. Anti-infective
7.2.3. Anticancer
7.2.4. Neurological
7.2.5. Alimentary/Metabolic
7.2.6. Musculoskeletal
7.2.7. Cardiovascular Respiratory
7.2.8. Sensory
7.2.9. Others

Chapter 8. RNA Therapy Clinical Trials Market Segmentation 5: Regional Estimates & Trend Analysis

8.1. North America

8.1.1. North America RNA Therapy Clinical Trials Market revenue (US$ Million) estimates and forecasts By Modality, 2019-2031
8.1.2. North America RNA Therapy Clinical Trials Market revenue (US$ Million) estimates and forecasts By Clinical Trials Phase, 2019-2031
8.1.3. North America RNA Therapy Clinical Trials Market revenue (US$ Million) estimates and forecasts By Therapeutic Areas, 2019-2031
8.1.4. North America RNA Therapy Clinical Trials Market revenue (US$ Million) estimates and forecasts by country, 2019-2031

8.1.4.1. U.S.
8.1.4.2. Canada

8.2. Europe

8.2.1. Europe RNA Therapy Clinical Trials Market revenue (US$ Million) By Modality, 2019-2031
8.2.2. Europe RNA Therapy Clinical Trials Market revenue (US$ Million) estimates and forecasts By Clinical Trials Phase, 2019-2031
8.2.3. Europe RNA Therapy Clinical Trials Market revenue (US$ Million) estimates and forecasts By Therapeutic Areas 2019-2031
8.2.4. Europe RNA Therapy Clinical Trials Market revenue (US$ Million) by country, 2019-2031

8.2.4.1. Germany
8.2.4.2. Poland
8.2.4.3. France
8.2.4.4. Italy
8.2.4.5. Spain
8.2.4.6. UK
8.2.4.7. Rest of Europe

8.3. Asia Pacific

8.3.1. Asia Pacific RNA Therapy Clinical Trials Market revenue (US$ Million) by Modality, 2019-2031
8.3.2. Asia Pacific RNA Therapy Clinical Trials Market revenue (US$ Million) estimates and forecasts By Clinical Trials Phase, 2019-2031
8.3.3. Asia Pacific RNA Therapy Clinical Trials Market revenue (US$ Million) estimates and forecasts By Therapeutic Areas, 2019-2031
8.3.4. Asia Pacific RNA Therapy Clinical Trials Market revenue (US$ Million) by country, 2019-2031

8.3.4.1. China
8.3.4.2. India
8.3.4.3. Japan
8.3.4.4. Australia
8.3.4.5. Rest of Asia Pacific

8.4. Latin America

8.4.1. Latin America RNA Therapy Clinical Trials Market revenue (US$ Million) by Modality, 2019-2031
8.4.2. Latin America RNA Therapy Clinical Trials Market revenue (US$ Million) estimates and forecasts Clinical Trials Phase 2019-2031
8.4.3. Latin America RNA Therapy Clinical Trials Market revenue (US$ Million) estimates and forecasts By Therapeutic Areas, 2019-2031
8.4.4. Latin America RNA Therapy Clinical Trials Market revenue (US$ Million) by country, (US$ Million) 2019-2031

8.4.4.1. Brazil
8.4.4.2. Rest of Latin America

8.5. Middle East & Africa

8.5.1. Middle East & Africa RNA Therapy Clinical Trials Market revenue (US$ Million) By Modality, (US$ Million)
8.5.2. Middle East & Africa RNA Therapy Clinical Trials Market revenue (US$ Million) estimates and forecasts By Clinical Trials Phase, 2019-2031
8.5.3. Middle East & Africa RNA Therapy Clinical Trials Market revenue (US$ Million) estimates and forecasts By Therapeutic Areas, 2019-2031
8.5.4. Middle East & Africa RNA Therapy Clinical Trials Market revenue (US$ Million) by country, (US$ Million) 2019-2031South Africa

8.5.4.1. GCC Countries
8.5.4.2. Rest of MEA

Chapter 9. Competitive Landscape

9.1. Major Mergers and Acquisitions/Strategic Alliances

9.2. Company Profiles

9.2.1. IQVIA
9.2.2. ICON Plc
9.2.3. Laboratory Corporation of America Holdings
9.2.4. Charles River Laboratories International, Inc.
9.2.5. PAREXEL International Corp.
9.2.6. Syneos Health
9.2.7. Medpace Holdings, Inc.
9.2.8. PPD Inc.
9.2.9. Novotech
9.2.10. Veristat, LLC.

Segmentation of RNA Therapy Clinical Trials Market-

RNA Therapy Clinical Trials Market By Modality-

  • RNA interference
  • Antisense therapy
  • Messenger RNA
  • Oligonucleotide, non-antisense, non-RNAi)

RNA Therapy Clinical Trials Market

RNA Therapy Clinical Trials Market By Clinical Trials Phase-

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

RNA Therapy Clinical Trials Market By Therapeutic Areas-

  • Rare Diseases
  • Anti-infective
  • Anticancer
  • Neurological
  • Alimentary/Metabolic
  • Musculoskeletal
  • Cardiovascular Respiratory
  • Sensory
  • Others

RNA Therapy Clinical Trials Market By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of the Middle East and Africa

 InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

user icon
office icon
mail icon
call icon

This website is secure, and we do not share your personal information with any third party. Privacy Policy

Need Customization
Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Frequently Asked Questions

How big is the RNA Therapy Clinical Trials Market ?

RNA Therapy Clinical Trials Market expected to grow at a 3.6% CAGR during the forecast period for 2023-2031

IQVIA; ICON Plc; Laboratory Corporation of America Holdings; Charles River Laboratories International, Inc.; PAREXEL International Corp.; Syneos Healt

Our Clients

  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo

Media Citations

  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo

Growth opportunities and latent adjacency in Biotechnology

Select Licence Type
$4456
$7786
$10000
$1200
Get Your GTM Strategy

Navigate market entry with channel selection, launch strategy & timeline, and pricing model support.

Equip yourself with the insights needed to develop a winning go-to-market strategy

Get real-time updates and joint control over project direction with our collaborative approach